Fig. 5: Deletion of Fasn alters the cellular lipidome in vitro and in vivo.
From: De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics
Lipidomics analyses from in vitro differentiated FasnFl/Fl and cAdFasnKO primary adipocytes and subcutaneous WAT from FasnFl/Fl and iAdFasnKO mice. a Relative amounts of different lipid classes from in vitro differentiated adipocytes and (b) in vivo iWAT. Two-tailed t tests: P Values = (a) from left to right <0.00001, 0.000738, 0.061515, 0.004430, 0.061515. 0.054831, 0.001855, 0.000028, 0.00042, 0.013057, 0.016585, <0.00001, (b) from left to right 0.178372, 0.820148, 0.057631, 0.284882, 0.041275, 0.580865, 0.50506, 0.457181, 0.184524, 0.90473, 0.141867, 0.885965, *<0.05, **<0.01, ***<0.001, ****<0.0001. Fatty acyl chain composition of different lipid classes in vitro (c) and in vivo (d). Percent of indicated lipid containing fatty acid chains ≤ 16 carbons vs. lipids with fatty acid chains ≥ 18 carbons. n = 3 samples for in vitro analyses. n = 4 mice for in vivo analyses. All data are means ± SE. Two-way ANOVA with Sidak post hoc, P values = (c) from left to right <0.00001/<0.00001, <0.00001/<0.00001, <0.00001/<0.00001, <0.00001/<0.00001, (d) from left to right <0.00001/<0.00001, <0.00001/<0.00001, <0.00001/<0.00001, 0.0375/0.0375, *<0.05, ****<0.0001. PE phosphatidylethanolamine, PI phosphatidylinositol, PS phosphatidylserine, PG phosphatidylglycerol, SM sphingomyelin, PC phosphatidylcholine, PA phosphatidic acid, CL cardiolipin, Cer ceramide, LPE lysophosphatidylethanolamine, LPC lysophosphatidylcholine, LCL lysocardiolipin. Source data are provided as a Source Data file.
